|
|
2015 Featured Talks » A novel bispecific antibody targeting EGFR and cMet with multiple mechanisms of action
Mark Anderson, part 1 from MCC Industry Relations on Vimeo.
Mark Anderson, part 2 from MCC Industry Relations on Vimeo.
Mark Anderson, PhD
Scientific Director of Oncology Research
Janssen Pharmaceuticals
Dr. Mark Anderson is a Scientific Director of Oncology Research at Janssen Pharmaceuticals, the pharmaceutical division of Johnson&Johnson. He leads a discovery team focused on the preclinical development of biologically based therapeutics for cancer. He received his Ph.D. in Biological Chemistry from the University of Michigan in Ann Arbor and conducted his postdoctoral training at Merck Research Laboratories in West Point, Pennsylvania. Prior to joining J&J in 2001, Dr. Anderson spent several years in the biotechnology industry discovering and developing innate immune stimulants and anti-cancer agents at Magainin Pharmaceuticals. He has published numerous peer-reviewed journal articles, book chapters, and patents in the areas of transcription control, innate immunity, cancer biology, and biologic cancer therapeutics. Dr. Anderson’s teams have progressed several novel agents from the discovery stage to clinical testing. His laboratory has focused on the development of antibodies, antibody drug conjugates, novel biologic scaffolds, and recently bispecific antibodies for the treatment of cancer.
|
